



EASL

EUROPEAN
ASSOCIATION
FOR THE STUDY
OF THE LIVER

**MONOTHEMATIC
CONFERENCE**

LYON. FRANCE

NOVEMBER 29 - 30 / 2013

**TRANSLATIONAL RESEARCH
IN CHRONIC VIRAL HEPATITIS
- BRIDGING BASIC SCIENCE
AND CLINICAL RESEARCH**

[https://events.easl.eu/EventPortal/
Information/MLYON2013/HOME.aspx](https://events.easl.eu/EventPortal/Information/MLYON2013/HOME.aspx)



Abstract submission deadline:
August 16, 2013

SCIENTIFIC ORGANISING COMMITTEE:

D. Moradpour, R. Thimme, F. Zoulim

Sponsored by



Bristol-Myers Squibb



GILEAD



MSD



Join EASL on Facebook
www.easl.eu/fb



Follow EASL on Twitter
www.easl.eu/twitter

PRELIMINARY PROGRAMME

EASL Monothematic Conference:

Translational Research in Chronic Viral Hepatitis Bridging Basic Science and Clinical Research

Lyon, France, November 28-30, 2013

EASL scientific organisers:

D. Moradpour, Lausanne, Switzerland

R. Thimme, Freiburg, Germany

F. Zoulim, Lyon, France

Thursday, November 28, 2013

16:00 – 20:00 REGISTRATION


Day 1 - Friday, November 29, 2013

- | | |
|----------------------|---|
| 8.30 | Welcome and introductory remarks
Fabien Zoulim, Lyon, France |
| 8.45 | Keynote lecture
What have we learned from the history of viral hepatitis research ?
Hubert Blum, Freiburg, Germany |
| 9.15 – 10.15 | Viral replication and new antiviral targets
Chairs : François Penin, Lyon, France
David Durantel, Lyon, France |
| 9.15 | The HCV life cycle – tools and concepts
Ralf Bartenschlager, Heidelberg, Germany |
| 9.45 | The HBV life cycle – tools and concepts
Stephan Urban, Heidelberg, Germany |
| 10.15 – 10.45 | Coffee break and posters |
| 10.45 – 12.15 | Cell culture models - how do they translate to the human situation ?
Chairs : Jean Dubuisson, Lille, France
Birke Bartosch, Lyon, France |
| 10.45 | HBV – cccDNA formation and regulation
Michael Nassal, Freiburg, Germany |
| 11.15 | HCV – virus-host cell interactions
Thomas Baumert, Strasbourg, France |
| 11.45 | HBV/HDV coinfections
Camille Sureau, Paris, France |

EASL MONOTHEMATIC CONFERENCE

TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS – BRIDGING BASIC SCIENCE
AND CLINICAL RESEARCH

- 12.15 – 13.30 Lunch break and posters**
- 13.30 – 15.30 Studies in Animal Models**
Chairs : Lucyna Cova, Lyon, France
Volker Lohmann, Heidelberg, Germany
- 13.30 Humanized mouse models for HBV – applications
Maura Dandri, Hamburg, Germany
- 14.00 Humanized mouse models for HCV – applications
Philip Meuleman, Ghent , Belgium
- 14.30 Challenges with the development of immune competent mouse models
Alexander Ploss, New York, USA
- 15.00 Lessons learned from chimpanzee studies in HBV and HCV
Jens Bukh, Hvidovre, Denmark
- 15.30 – 16.00 Coffee break and posters**
- 16.00 – 17.30 What have we learned from clinical cohort studies ?**
Chairs : Mark Thursz, London, UK
Joerg Petersen, Hamburg, Germany
- 16.00 HepNet cohort
Markus Cornberg, Hannover, Germany
- 16.15 Swiss hepatitis C cohort study
Francesco Negro, Geneva, Switzerland
- 16.30 French ANRS CUPIC/HEPATHE cohort
Stanislas Pol, Paris, France
- 16.45 Large population based cohort studies and translational studies
Vincent Mooser, Lausanne, Switzerland
- 17.15 Round table discussion : What to do and what not to do ?
- 17.30 – 19.00 Oral communications**
Chairs : Romain Parent, Lyon, France
Marlène Dreux, Lyon, France
Young investigators – selected abstracts (6 communications)
- 19.00 – 20.00 Cocktail reception**



Day 2 - Saturday, November 30, 2013

08.00 – 9.30 Translational immunology (Part I)

Chairs : Paul Kleernan, Oxford, UK
Ulrike Protzer, Munich, Germany

8.00 State of the art technology to study HBV and HCV specific immune responses
Gabriele Missale, Parma, Italy

8.30 HBV innate immune responses
Mala Maini, London, UK

9.00 HCV innate immune responses
Markus Heim, Basel Switzerland

9.30 – 10.00 Coffee break and posters

10.00 – 11.30 Translational immunology (Part II)

Chairs : Paul Kleernan, Oxford, UK
Ulrike Protzer, Munich, Germany

10.00 Novel insights into the role of NK cells in HBV and HCV infection
Salim Khakoo, Southampton, UK

10.30 T cell responses in HBV and HCV: what we know and what we need to learn ?
Robert Thimme, Freiburg, Germany

11.00 Present and future of immunotherapeutic approaches to viral hepatitis
Eleanor Barnes, Oxford, UK

11.30 – 12.30 New technologies for translational research (Part I)

Chairs : Eve-Isabelle Pecheur, Lyon, France
Thomas Pietschmann, Hannover, Germany

11.30 Functional and biochemical characterization of HCV particles produced in vivo: a comparison with HCVcc models
François-Loïc Cosset, Lyon, France

12.00 Stem cells derived hepatocytes as in vitro study models of HBV and HCV infections
Catherine Verfaillie, Leuven, Belgium

12.30 – 13.30 Lunch break and posters

13.30 Next generation sequencing for hepatitis viruses
Robert Shafer, Stanford, USA

14.00 Data bases and modeling
Christophe Combet, Lyon, France

EASL MONOTHEMATIC CONFERENCE

TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS – BRIDGING BASIC SCIENCE
AND CLINICAL RESEARCH

14.30 – 17.00 New technologies for translational research (Part II)

Chairs : Markus Heim, Basel, Switzerland
Isabelle Chemin, Lyon, France

14.30 Epigenetic regulation of cccDNA : insights into the pathogenesis and treatment of HBV infection
Massimo Levrero, Roma, Italy

15:00 Expanding the toolbox for genetic studies: GWAS and beyond
Jacques Fellay, Lausanne, Switzerland

15:30 Should we go for all « omics » studies ?
Vincent Lotteau, Lyon, France

16:00 Identification of Biomarkers
HBV – Host genetics and disease outcome
Mark Thursz, London, UK

16.30 HCV – Prediction of disease/treatment outcome
Matthew Albert, Paris, France

17.00 – 17.30 Coffee break and posters

17.30 – 18.30 Treatment perspectives

Chairs : Christian Trépo, Lyon, France
Heiner Wedemeyer, Hannover, Germany

Towards new concepts for HBV therapy
Fabien Zoulim, Lyon, France

Perspectives for the treatment of chronic hepatitis C
Darius Moradpour, Lausanne, Switzerland

EASL MONOTHEMATIC CONFERENCE

TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS – BRIDGING BASIC SCIENCE
AND CLINICAL RESEARCH